-
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
Bast RC Jr,
Klug TL,
St John E,
Jenison E,
Niloff JM,
Lazarus H,
Berkowitz RS,
Leavitt T,
Griffiths CT,
Parker L,
Zurawski VR Jr,
Knapp RC.
The murine monoclonal antibody OC 125 reacts with an antigen (CA 125) common to most nonmucinous epithelial ovarian carcinomas. An assay has been developed to detect CA 125 in serum. By this assay, only 1 per cent of 888 apparently healthy persons and 6 per cent of 143 patients with nonmalignant disease had serum CA 125 levels above 35 U per milliliter. In contrast, 83 of 101 patients (82 per cent) with surgically demonstrated ovarian carcinoma had elevated levels of antigen. In 38 patients with epithelial ovarian carcinoma monitored on 2 to 18 occasions during 2 to 60 months, antigen levels ranged from less than 1 to more than 8000 U per milliliter. Rising or falling levels of CA 125 correlated with progression or regression of disease in 42 of 45 instances (93 per cent). Determination of CA 125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer.
PMID: 6310399 [PubMed - indexed for MEDLINE]
-
Cited by 34 PubMed Central articles
-
Towards an integrated proteomic and glycomic approach to finding cancer biomarkers.
Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM.
Genome Med. 2009 Jun 4; 1(6):57. Epub 2009 Jun 4.
[Genome Med. 2009]
-
Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.
Yoo SC, Yoon JH, Lyu MO, Kim WY, Chang SJ, Chang KH, Ryu HS.
J Gynecol Oncol. 2008 Sep; 19(3):169-72. Epub 2008 Sep 30.
[J Gynecol Oncol. 2008]
-
MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.
Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR.
Differentiation. 2008 Dec; 76(10):1081-92. Epub 2008 Jul 2.
[Differentiation. 2008]
- » See all...